Published in Mol Ther on September 01, 2006
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature (2011) 4.61
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer (2009) 3.06
Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest (2007) 2.36
Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med (2007) 2.15
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 2.14
Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 1.87
Viruses as anticancer drugs. Trends Pharmacol Sci (2007) 1.63
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. Clin Cancer Res (2015) 1.61
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther (2011) 1.59
Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov (2015) 1.47
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther (2011) 1.45
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther (2011) 1.39
Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther (2011) 1.26
Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res (2014) 1.23
"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther (2009) 1.20
T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther (2013) 1.07
Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol Ther (2010) 1.05
Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming. Mol Cancer (2011) 1.04
The evolution of poxvirus vaccines. Viruses (2015) 1.02
Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther (2009) 1.02
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin Cancer Res (2011) 1.00
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer. Mol Ther (2015) 0.97
Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol Ther (2012) 0.96
Glioma virus therapies between bench and bedside. Neuro Oncol (2014) 0.95
Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours. Gene Ther (2009) 0.94
UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells. Blood (2016) 0.90
From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer. PLoS Pathog (2014) 0.90
Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther (2013) 0.90
Gamma interferon and perforin control the strength, but not the hierarchy, of immunodominance of an antiviral CD8+ T cell response. J Virol (2011) 0.88
Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. Mol Ther (2015) 0.87
Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines. BMB Rep (2015) 0.87
Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin. Neuro Oncol (2013) 0.87
Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. Mol Ther Methods Clin Dev (2016) 0.86
Features of the Antitumor Effect of Vaccinia Virus Lister Strain. Viruses (2016) 0.86
Theranostic potential of oncolytic vaccinia virus. Theranostics (2012) 0.86
Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci (2016) 0.86
Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer. Front Oncol (2014) 0.85
Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther (2009) 0.84
Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling. Gene Ther (2011) 0.84
Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer. J Transl Med (2015) 0.83
Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data. Hum Gene Ther (2015) 0.83
Oncolytic vaccinia virotherapy for endometrial cancer. Gynecol Oncol (2014) 0.82
Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1. Front Oncol (2014) 0.82
A selectable and excisable marker system for the rapid creation of recombinant poxviruses. PLoS One (2011) 0.82
Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses. Microb Biotechnol (2011) 0.82
Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. Mol Ther (2010) 0.81
Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma. Oncolytic Virother (2013) 0.80
Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses (2015) 0.80
Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF. Int J Cancer (2014) 0.80
Novel delivery methods to achieve immunomodulation. Curr Opin Pharmacol (2007) 0.80
Sorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma. Front Oncol (2014) 0.80
Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbits. J Virol (2007) 0.80
Giving oncolytic vaccinia virus more BiTE. Mol Ther (2014) 0.79
Oncolytic virotherapy for advanced liver tumours. J Cell Mol Med (2008) 0.79
Oncolytic Viruses: Therapeutics With an Identity Crisis. EBioMedicine (2016) 0.79
Oncolytic virus therapy for cancer. Oncolytic Virother (2013) 0.78
Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice. J Exp Clin Cancer Res (2015) 0.78
Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapy. J Transl Med (2012) 0.78
Oncolytic viruses in the treatment of bladder cancer. Adv Urol (2012) 0.78
Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization. Biomedicines (2016) 0.77
Viroimmunotherapy for Colorectal Cancer: Clinical Studies. Biomedicines (2017) 0.77
Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses. Oncolytic Virother (2013) 0.77
Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"? Mol Ther Oncolytics (2015) 0.77
Interfering with tumor pathways that augment viral oncolysis. Mol Ther (2011) 0.77
Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery. Front Oncol (2017) 0.76
Viruses as nanomedicine for cancer. Int J Nanomedicine (2016) 0.76
Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy. Viruses (2015) 0.76
Oncolytic bluetongue viruses: promise, progress, and perspectives. Front Microbiol (2011) 0.76
A pox on your tumor. Mol Ther (2006) 0.75
Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models. J Hepatocell Carcinoma (2014) 0.75
The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594). Oncolytic Virother (2015) 0.75
Gene and virotherapy for hematological malignancies. Int J Hematol (2016) 0.75
Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy. Cancer Cell (2016) 0.75
Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. Mediators Inflamm (2017) 0.75
Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy. Gene Ther (2016) 0.75
Cytotoxic effect of a combination of bluetongue virus and radiation on prostate cancer. Exp Ther Med (2014) 0.75
Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes. Onco Targets Ther (2017) 0.75
Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet (2000) 5.50
An essential role for Rac in Ras transformation. Nature (1995) 5.34
Infection and nitroblue-tetrazolium reduction by neutrophils. A diagnostic acid. Lancet (1968) 5.30
Role of BAX in the apoptotic response to anticancer agents. Science (2000) 5.07
The many mechanisms of viral membrane fusion proteins. Curr Top Microbiol Immunol (2005) 4.19
Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther (2011) 3.56
CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP. Cell (1995) 3.46
Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem (2001) 3.27
Emerging invasive liver abscess caused by K1 serotype Klebsiella pneumoniae in Korea. J Infect (2006) 3.04
Mutation of the PIK3CA oncogene in human cancers. Br J Cancer (2006) 3.04
Electron microscope heteroduplex study of sequence relations of T2, T4, and T6 bacteriophage DNAs. Virology (1974) 2.82
Syndrome of cerebral spinal fluid hypovolemia: clinical and imaging features and outcome. Neurology (2000) 2.76
Heteroduplex structures of bacteriophage Mu DNA. Virology (1973) 2.52
Abnormal cardiac conduction and morphogenesis in connexin40 and connexin43 double-deficient mice. Circ Res (2000) 2.37
Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest (1993) 2.29
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med (2000) 2.24
Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet (1997) 2.20
Abdominal amyloidosis: spectrum of radiological findings. Clin Radiol (2003) 2.10
Incidence and natural history of deep-vein thrombosis after total hip arthroplasty. A prospective and randomised clinical study. J Bone Joint Surg Br (2003) 2.10
Guillain-Barré syndrome: MR imaging findings of the spine in eight patients. Radiology (1998) 2.08
Thrombotic thrombocytopenic purpura associated with ticlopidine use: a report of 3 cases and review of the literature. Arch Intern Med (1999) 2.08
Rapid appearance of new cerebral microbleeds after acute ischemic stroke. Neurology (2009) 2.08
A role for C/EBPbeta in regulating peroxisome proliferator-activated receptor gamma activity during adipogenesis in 3T3-L1 preadipocytes. J Biol Chem (2001) 2.07
Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol (2001) 2.03
A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A (1990) 2.03
Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B. Neurology (2011) 2.03
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene (2012) 1.98
Intracranial stenting of severe symptomatic intracranial stenosis: results of 100 consecutive patients. AJNR Am J Neuroradiol (2008) 1.93
Mutations in the rpoB gene of Mycobacterium tuberculosis that interfere with PCR-single-strand conformation polymorphism analysis for rifampin susceptibility testing. J Clin Microbiol (1997) 1.89
Biliary papillomatosis: clinical, cholangiographic and cholangioscopic findings. Endoscopy (1998) 1.85
Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol (2007) 1.84
High-speed fiber based polarization-sensitive optical coherence tomography of in vivo human skin. Opt Lett (2000) 1.82
Cyclobutane pyrimidine dimers are responsible for the vast majority of mutations induced by UVB irradiation in mammalian cells. J Biol Chem (2001) 1.80
Which cholesterol level is related to the lowest mortality in a population with low mean cholesterol level: a 6.4-year follow-up study of 482,472 Korean men. Am J Epidemiol (2000) 1.79
6,7-Bis(bromomethyl)-2,11,18,21,24-pentaoxatetracyclo. Acta Crystallogr C (2001) 1.79
Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery (1993) 1.79
Rotational vertebral artery syndrome: oculographic analysis of nystagmus. Neurology (2005) 1.73
Energy-dependent efflux mediated by class L (tetL) tetracycline resistance determinant from streptococci. Antimicrob Agents Chemother (1987) 1.72
B and T lymphocytes in primary immunodeficiency disease in man. J Clin Invest (1973) 1.72
High-resolution crystal structures of delta5-3-ketosteroid isomerase with and without a reaction intermediate analogue. Biochemistry (1997) 1.71
Comparison of endoscopic ultrasonography and conventional endoscopy for prediction of depth of tumor invasion in early gastric cancer. Endoscopy (2010) 1.70
Water: now you see it, now you don't. Structure (1993) 1.70
Serum antibodies to cow's milk proteins in ulcerative colitis and Crohn's disease. Gastroenterology (1987) 1.70
A comparison of polyethylene wear in hips with cobalt-chrome or zirconia heads. A prospective, randomised study. J Bone Joint Surg Br (2001) 1.68
Suppression of the Fix- phenotype of Rhizobium meliloti exoB mutants by lpsZ is correlated to a modified expression of the K polysaccharide. J Bacteriol (1995) 1.66
Virulence factors of Helicobacter pylori in Korean isolates do not influence proinflammatory cytokine gene expression and apoptosis in human gastric epithelial cells, nor do these factors influence the clinical outcome. J Gastroenterol (2000) 1.62
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59
TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition. Oncogene (2007) 1.58
Comparison of total hip replacement with and without cement in patients younger than 50 years of age: the results at 18 years. J Bone Joint Surg Br (2011) 1.57
Defective vascular development in connexin 45-deficient mice. Development (2000) 1.57
Strain distribution in the proximal human femur. An in vitro comparison in the intact femur and after insertion of reference and experimental femoral stems. J Bone Joint Surg Br (2001) 1.56
Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res (2000) 1.55
Central neurocytoma: proliferative potential and biological behavior. J Neurosurg (1996) 1.55
Head-shaking nystagmus in lateral medullary infarction: patterns and possible mechanisms. Neurology (2007) 1.54
Pulmonary damage by Vibrio vulnificus cytolysin. Infect Immun (1996) 1.53
Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther (2008) 1.52
High-speed polarization sensitive optical frequency domain imaging with frequency multiplexing. Opt Express (2008) 1.52
Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol (2007) 1.50
Spectral domain optical coherence tomography for quantitative evaluation of drusen and associated structural changes in non-neovascular age-related macular degeneration. Br J Ophthalmol (2008) 1.49
Peripheral blood mitochondrial DNA content is related to insulin sensitivity in offspring of type 2 diabetic patients. Diabetes Care (2001) 1.49
Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer (1999) 1.48
Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett (1980) 1.48
A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci U S A (1996) 1.48
Primary stenting for acute myocardial infarction via the transradial approach: a safe and useful alternative to the transfemoral approach. J Invasive Cardiol (2000) 1.47
Phenylpropanolamine contained in cold remedies and risk of hemorrhagic stroke. Neurology (2007) 1.47
The human RAE1 gene is a functional homologue of Schizosaccharomyces pombe rae1 gene involved in nuclear export of Poly(A)+ RNA. Gene (1997) 1.45
Association of angiotensin I converting enzyme gene polymorphism with reflux nephropathy in children. Nephron (2000) 1.44
Alfentanil reduces the febrile response to interleukin-2 in humans. Crit Care Med (2000) 1.44
A new hereditary cataract mouse with lens rupture. Lab Anim (1997) 1.44
Differential effects of cAMP in neurons and astrocytes. Role of B-raf. J Biol Chem (1999) 1.43
Cerebral glucose metabolism in Fisher syndrome. J Neurol Neurosurg Psychiatry (2008) 1.42
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther (2001) 1.42
Single-stage operation for bilateral middle cerebral artery aneurysms. Acta Neurochir (Wien) (2005) 1.42
Production of cell-associated polysaccharides of Rhizobium fredii USDA205 is modulated by apigenin and host root extract. Mol Plant Microbe Interact (1994) 1.42
Repeat hepatic resection as effective treatment of recurrent colorectal liver metastases. Ann Surg Oncol (1997) 1.41
Optimal bolus dose of alfentanil for successful tracheal intubation during sevoflurane induction with and without nitrous oxide in children. Br J Anaesth (2010) 1.41
Bacteriophage T4 transfer RNA. 3. Clustering of the genes for the T4 transfer RNA's. J Mol Biol (1972) 1.41
Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg (1999) 1.39
Comparison of fixed-bearing and mobile-bearing total knee arthroplasties. Clin Orthop Relat Res (2001) 1.38
Chronic granulomatous disease in females. N Engl J Med (1970) 1.38
Long-term clinical course and prognostic factors in intestinal Behçet's disease. Dis Colon Rectum (2000) 1.37
Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther (2001) 1.37
Sinorhizobium fredii and Sinorhizobium meliloti produce structurally conserved lipopolysaccharides and strain-specific K antigens. Appl Environ Microbiol (1998) 1.36
Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther (2001) 1.36
The prevalence of trimethoprim-resistance-conferring dihydrofolate reductase genes in urinary isolates of Escherichia coli in Korea. J Antimicrob Chemother (2001) 1.34
Mucoepidermoid carcinoma of the tracheobronchial tree: radiographic and CT findings in 12 patients. Radiology (1999) 1.33
Prevalence of periodontal disease in insulin-dependent diabetes mellitus (juvenile diabetes). J Am Dent Assoc (1982) 1.33
Anisotropic Dirac fermions in a Bi square net of SrMnBi2. Phys Rev Lett (2011) 1.33
ATP-dependent degradation of SulA, a cell division inhibitor, by the HslVU protease in Escherichia coli. FEBS Lett (1999) 1.33
Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol (2007) 1.31
Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol (2000) 1.31
Bispectral EEG index during nitrous oxide administration. Anesthesiology (1998) 1.30
Aerobic fitness is associated with greater efficiency of the network underlying cognitive control in preadolescent children. Neuroscience (2011) 1.30
Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci U S A (1991) 1.29
Xanthogranulomatous cystitis associated with suture material. J Urol (1998) 1.29
Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res (1999) 1.28
Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol (2000) 1.27